Fox Chase Cancer Center News

PHILADELPHIA (November 24, 2017) – Researchers at Fox Chase Cancer Center and the Johns Hopkins University School of Medicine have identified two new subtypes of laryngeal cancer, each of which indicates different survival outcomes for patients. These findings, which for the first time linked better survival to mutations damaging the genes NSD1 and NSD2, were validated in an independent cohort of patients treated at Fox Chase and Johns Hopkins.

PHILADELPHIA (November 21, 2017) — The screening will be held at American Legion Post #366, 7976 Oxford Ave, on Wednesday November 29, 2017. Doors will open at 5:30 p.m. and Fundakowski and staff will provide the screenings.

Washington DC (November 20, 2017) — Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. This year 396 members have been awarded this honor because of their scientifically or socially distinguished efforts to advance science or its applications.

PHILADELPHIA (November 9, 2017) – Although it is recommended for all colorectal cancer patients, most are not being screened for a common genetic syndrome that increases the risk of several forms of cancer and can influence treatment outcomes, according to a new study in JAMA Oncology. In the largest U.S. study of its kind, researchers at Fox Chase Cancer Center found that only 28 percent of adult colorectal cancer patients undergoing colorectal cancer resection were reported to have MMR deficiency testing performed on their tumors.

PHILADELPHIA (November 1, 2017) – November is Pancreatic Cancer Awareness month, and Fox Chase Cancer Center remains steadfast in its commitment to pancreatic cancer research. The creation of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center will significantly accelerate the pace of pancreatic cancer research, and its impact will be felt regionally and nationally.

PHILADELPHIA (October 26, 2017) – Researchers at Fox Chase Cancer Center and University of California San Diego School of Medicine have published a seminal paper in Cell that outlines characteristics on the cell’s surface that could predict the mutated oncogenes that will be present in a patient’s cancer. Major Histocompatibility Complex class I (MHC-I) displays peptides from inside on the cell’s surface, which allows T-cells to detect foreign or mutated peptides that exist inside cells.

PHILADELPHIA (October 25, 2017) – Fox Chase Cancer Center has partnered with Suburban Community Hospital to open the Fox Chase Cancer Center East Norriton Hospital Outpatient Center. The center will open in 2018 and offer access to Fox Chase’s multidisciplinary care by surgical oncologists, hematologists/oncologists, radiation oncologists, and support staff including onsite radiation and infusion treatments.

PHILADELPHIA (October 25, 2017) – David Wiest, PhD, deputy chief scientific officer and co-leader of blood cell development and function at Fox Chase Cancer Center, has been appointed to the NCI’s Board of Scientific Counselors for Basic Sciences.